RecruitingNot Applicable

Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

Italy1,941 participantsStarted 2026-02-20

Plain-language summary

To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and \< 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a matched control cohort of same AML patients treated with intensive chemotherapy. In addittion, to further validate the efficacy of the VEN-DEC treatment approach in elderly AML patients, an advanced generative AI model will be constructed and trained using the historical cohort data. The AI model aims to simulate outcomes based on the standard

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with AML treated with cht (historical cohort) or VenDec (experimental cohort) Exclusion Criteria: \-

What they're measuring

Propensity Score Matching (PSM) objective

Timeframe: 8-12 months

Artificial Intelligence objectives

Timeframe: 8-12 months

Trial details

NCT IDNCT07420790

SponsorAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

Contact for this trial

Domenico Russo, MD

00390303996811 domenico.russo@unibs.it

View on ClinicalTrials.gov More Acute Myeloid Leukemia trials